{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T21:53:58Z","timestamp":1774130038171,"version":"3.50.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T00:00:00Z","timestamp":1688774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T00:00:00Z","timestamp":1688774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01 HL152677"],"award-info":[{"award-number":["R01 HL152677"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["RO1 AR073270"],"award-info":[{"award-number":["RO1 AR073270"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Many clinical trial results are available to inform best practices in the treatment of patients with connective tissue disease-associated interstitial lung disease (CTD-ILD).<\/jats:p><jats:p>Herein, we summarize the results of clinical trials, including patient-reported outcome instruments, for the treatment of patients with ILD associated with systemic sclerosis (SSc\/scleroderma), rheumatoid arthritis, and idiopathic inflammatory myositis, the diseases with the most available data. For SSc-ILD, the US Food and Drug Administration approved nintedanib (a tyrosine kinase inhibitor) in 2020 and subcutaneous tocilizumab (an IL-6 receptor monoclonal antibody) in 2021. Rituximab was recently shown to have similar efficacy but better tolerability than intravenous cyclophosphamide (CYC) for CTD-ILD therapy. Scleroderma Lung Study II, conducted in patients with SSc-ILD, showed that oral CYC and mycophenolate mofetil (MMF) were comparable in their effects on lung function, but MMF was better tolerated. The increasing treatment armamentarium for patients with CTD-ILD offers physicians new opportunities to improve patient outcomes.<\/jats:p>","DOI":"10.1186\/s13075-023-03090-y","type":"journal-article","created":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T06:01:41Z","timestamp":1688796101000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Learnings from clinical trials in patients with connective tissue disease-associated interstitial lung disease"],"prefix":"10.1186","volume":"25","author":[{"given":"Jean Paul","family":"Higuero Sevilla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Areeka","family":"Memon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8652-9890","authenticated-orcid":false,"given":"Monique","family":"Hinchcliff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,8]]},"reference":[{"issue":"7","key":"3090_CR1","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1136\/ard.2006.066068","volume":"66","author":"VD Steen","year":"2007","unstructured":"Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972\u20132002. Ann Rheum Dis. 2007;66(7):940\u20134.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"3090_CR2","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an Official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022;205(9):e18-47.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"3090_CR3","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/S2213-2600(19)30480-1","volume":"8","author":"A Perelas","year":"2020","unstructured":"Perelas A, Silver RM, Arrossi AV, Highland KB. Systemic sclerosis-associated interstitial lung disease. Lancet Respir Med. 2020;8(3):304\u201320.","journal-title":"Lancet Respir Med"},{"issue":"3","key":"3090_CR4","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1136\/ard.2003.006122","volume":"63","author":"M Fathi","year":"2004","unstructured":"Fathi M, Dastmalchi M, Rasmussen E, Lundberg IE, Tornling G. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis. 2004;63(3):297\u2013301.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"3090_CR5","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1002\/art.40574","volume":"70","author":"P Spagnolo","year":"2018","unstructured":"Spagnolo P, Lee JS, Sverzellati N, Rossi G, Cottin V. The lung in rheumatoid arthritis: focus on interstitial lung disease. Arthritis Rheumatol. 2018;70(10):1544\u201354.","journal-title":"Arthritis Rheumatol"},{"key":"3090_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.610257","volume":"7","author":"R Amarnani","year":"2020","unstructured":"Amarnani R, Yeoh SA, Denneny EK, Wincup C. Lupus and the lungs: the assessment and management of pulmonary manifestations of systemic lupus erythematosus. Front Med (Lausanne). 2020;7: 610257.","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"3090_CR7","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.chest.2020.10.011","volume":"159","author":"AS Lee","year":"2021","unstructured":"Lee AS, Scofield RH, Hammitt KM, Gupta N, Thomas DE, Moua T, et al. Consensus guidelines for evaluation and management of pulmonary disease in Sjogren\u2019s. Chest. 2021;159(2):683\u201398.","journal-title":"Chest"},{"issue":"4","key":"3090_CR8","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3390\/diagnostics10040208","volume":"10","author":"D Sambataro","year":"2020","unstructured":"Sambataro D, Sambataro G, Pignataro F, Zanframundo G, Codullo V, Fagone E, et al. Patients with interstitial lung disease secondary to autoimmune diseases: how to recognize them? Diagnostics (Basel). 2020;10(4):208.","journal-title":"Diagnostics (Basel)"},{"issue":"11","key":"3090_CR9","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1007\/s10067-018-4289-6","volume":"37","author":"X Dong","year":"2018","unstructured":"Dong X, Zhou J, Guo X, Li Y, Xu Y, Fu Q, et al. A retrospective analysis of distinguishing features of chest HRCT and clinical manifestation in primary Sjogren\u2019s syndrome-related interstitial lung disease in a Chinese population. Clin Rheumatol. 2018;37(11):2981\u20138.","journal-title":"Clin Rheumatol"},{"issue":"22","key":"3090_CR10","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071\u201382.","journal-title":"N Engl J Med"},{"issue":"22","key":"3090_CR11","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"370","author":"TE King Jr","year":"2014","unstructured":"King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083\u201392.","journal-title":"N Engl J Med"},{"key":"3090_CR12","doi-asserted-by":"crossref","unstructured":"Idiopathic Pulmonary Fibrosis Clinical Research N, Raghu G, Anstrom KJ, King TE, Jr., Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366(21):1968\u201377.","DOI":"10.1056\/NEJMoa1113354"},{"issue":"1","key":"3090_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","volume":"11","author":"TM Maher","year":"2023","unstructured":"Maher TM, Tudor VA, Saunders P, Gibbons MA, Fletcher SV, Denton CP, et al. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. Lancet Respir Med. 2023;11(1):45\u201354.","journal-title":"Lancet Respir Med"},{"issue":"9","key":"3090_CR14","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4(9):708\u201319.","journal-title":"Lancet Respir Med"},{"issue":"26","key":"3090_CR15","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380(26):2518\u201328.","journal-title":"N Engl J Med"},{"issue":"25","key":"3090_CR16","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1056\/NEJMoa055120","volume":"354","author":"DP Tashkin","year":"2006","unstructured":"Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354(25):2655\u201366.","journal-title":"N Engl J Med"},{"issue":"1","key":"3090_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/2397198320915042","volume":"6","author":"ER Volkmann","year":"2021","unstructured":"Volkmann ER, Fischer A. Update on morbidity and mortality in systemic sclerosis-related interstitial lung disease. J Scleroderma Relat Disord. 2021;6(1):11\u201320.","journal-title":"J Scleroderma Relat Disord"},{"key":"3090_CR18","doi-asserted-by":"crossref","unstructured":"Ando K, Motojima S, Doi T, Nagaoka T, Kaneko N, Aoshima M, et al. Effect of glucocorticoid monotherapy on pulmonary function and survival in Japanese patients with scleroderma-related interstitial lung disease. Respir Investig. 2013;51(2):69\u201375.","DOI":"10.1016\/j.resinv.2012.12.002"},{"issue":"2","key":"3090_CR19","doi-asserted-by":"publisher","first-page":"84","DOI":"10.5301\/jsrd.5000234","volume":"2","author":"AL Herrick","year":"2017","unstructured":"Herrick AL. Controversies on the use of steroids in systemic sclerosis. J Scleroderma Relat Disord. 2017;2(2):84\u201391.","journal-title":"J Scleroderma Relat Disord"},{"issue":"10","key":"3090_CR20","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1164\/rccm.200702-326OC","volume":"176","author":"DP Tashkin","year":"2007","unstructured":"Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med. 2007;176(10):1026\u201334.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"3090_CR21","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1136\/annrheumdis-2018-213708","volume":"78","author":"ER Volkmann","year":"2019","unstructured":"Volkmann ER, Tashkin DP, Sim M, Li N, Goldmuntz E, Keyes-Elstein L, et al. Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts. Ann Rheum Dis. 2019;78(1):122\u201330.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"3090_CR22","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/rheumatology\/kep093","volume":"49","author":"D Daoussis","year":"2010","unstructured":"Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C, et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford). 2010;49(2):271\u201380.","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"3090_CR23","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327\u201339.","journal-title":"Ann Rheum Dis"},{"issue":"10038","key":"3090_CR24","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","volume":"387","author":"D Khanna","year":"2016","unstructured":"Khanna D, Denton CP, Jahreis A, van Laar JM, Frech TM, Anderson ME, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet. 2016;387(10038):2630\u201340.","journal-title":"Lancet"},{"issue":"10","key":"3090_CR25","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","volume":"8","author":"D Khanna","year":"2020","unstructured":"Khanna D, Lin CJF, Furst DE, Goldin J, Kim G, Kuwana M, et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2020;8(10):963\u201374.","journal-title":"Lancet Respir Med"},{"issue":"7","key":"3090_CR26","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1002\/art.41668","volume":"73","author":"D Roofeh","year":"2021","unstructured":"Roofeh D, Lin CJF, Goldin J, Kim GH, Furst DE, Denton CP, et al. Tocilizumab prevents progression of early systemic sclerosis associated interstitial lung disease. Arthritis Rheumatol. 2021;73(7):1301\u201310.","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"3090_CR27","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.semarthrit.2016.10.003","volume":"46","author":"D Daoussis","year":"2017","unstructured":"Daoussis D, Melissaropoulos K, Sakellaropoulos G, Antonopoulos I, Markatseli TE, Simopoulou T, et al. A multicenter, open-label, comparative study of B-cell depletion therapy with rituximab for systemic sclerosis-associated interstitial lung disease. Semin Arthritis Rheum. 2017;46(5):625\u201331.","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"3090_CR28","doi-asserted-by":"publisher","first-page":"e154","DOI":"10.1016\/S2665-9913(21)00418-5","volume":"4","author":"L Boekel","year":"2022","unstructured":"Boekel L, Wolbink GJ. Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients. Lancet Rheumatol. 2022;4(3):e154\u20135.","journal-title":"Lancet Rheumatol"},{"key":"3090_CR29","doi-asserted-by":"publisher","first-page":"e88","DOI":"10.1016\/S2665-9913(23)00004-8","volume":"5","author":"MY MdYusof","year":"2023","unstructured":"MdYusof MY, Arnold J, Saleem B, Vandevelde C, Dass S, Savic S, et al. Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study. Lancet Rheumatol. 2023;5:e88-98.","journal-title":"Lancet Rheumatol"},{"issue":"7","key":"3090_CR30","doi-asserted-by":"publisher","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","volume":"3","author":"S Ebata","year":"2021","unstructured":"Ebata S, Yoshizaki A, Oba K, Kashiwabara K, Ueda K, Uemura Y, et al. Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial. Lancet Rheumatol. 2021;3(7):e489\u201397.","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"3090_CR31","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1148\/radiol.2321030174","volume":"232","author":"N Tanaka","year":"2004","unstructured":"Tanaka N, Kim JS, Newell JD, Brown KK, Cool CD, Meehan R, et al. Rheumatoid arthritis-related lung diseases: CT findings. Radiology. 2004;232(1):81\u201391.","journal-title":"Radiology"},{"issue":"4","key":"3090_CR32","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/art.38322","volume":"66","author":"R Conway","year":"2014","unstructured":"Conway R, Low C, Coughlan RJ, O\u2019Donnell MJ, Carey JJ. Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheumatol. 2014;66(4):803\u201312.","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"3090_CR33","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1093\/rheumatology\/kex072","volume":"56","author":"MY MdYusof","year":"2017","unstructured":"MdYusof MY, Kabia A, Darby M, Lettieri G, Beirne P, Vital EM, et al. Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years\u2019 experience at a single centre. Rheumatology (Oxford). 2017;56(8):1348\u201357.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"3090_CR34","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3390\/jcm9010277","volume":"9","author":"G Cassone","year":"2020","unstructured":"Cassone G, Manfredi A, Atzeni F, Venerito V, Vacchi C, Picerno V, et al. Safety of abatacept in Italian patients with rheumatoid arthritis and interstitial lung disease: a multicenter retrospective study. J Clin Med. 2020;9(1):277.","journal-title":"J Clin Med"},{"issue":"1","key":"3090_CR35","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.semarthrit.2017.12.012","volume":"48","author":"C Fernandez-Diaz","year":"2018","unstructured":"Fernandez-Diaz C, Loricera J, Castaneda S, Lopez-Mejias R, Ojeda-Garcia C, Olive A, et al. Abatacept in patients with rheumatoid arthritis and interstitial lung disease: a national multicenter study of 63 patients. Semin Arthritis Rheum. 2018;48(1):22\u20137.","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"3090_CR36","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.chest.2016.04.007","volume":"150","author":"J Morisset","year":"2016","unstructured":"Morisset J, Johnson C, Rich E, Collard HR, Lee JS. Management of myositis-related interstitial lung disease. Chest. 2016;150(5):1118\u201328.","journal-title":"Chest"},{"issue":"5","key":"3090_CR37","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.chest.2019.05.023","volume":"156","author":"JA Huapaya","year":"2019","unstructured":"Huapaya JA, Silhan L, Pinal-Fernandez I, Casal-Dominguez M, Johnson C, Albayda J, et al. Long-term treatment with azathioprine and mycophenolate mofetil for myositis-related interstitial lung disease. Chest. 2019;156(5):896\u2013906.","journal-title":"Chest"},{"issue":"3","key":"3090_CR38","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1056\/NEJMc1900045","volume":"381","author":"Z Chen","year":"2019","unstructured":"Chen Z, Wang X, Ye S. Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease. N Engl J Med. 2019;381(3):291\u20133.","journal-title":"N Engl J Med"},{"issue":"5","key":"3090_CR39","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1183\/09031936.00174914","volume":"45","author":"L Wollin","year":"2015","unstructured":"Wollin L, Wex E, Pautsch A, Schnapp G, Hostettler KE, Stowasser S, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J. 2015;45(5):1434\u201345.","journal-title":"Eur Respir J"},{"issue":"5","key":"3090_CR40","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1007\/s12325-023-02454-9","volume":"40","author":"AJ Podolanczuk","year":"2023","unstructured":"Podolanczuk AJ, Cottin V. A narrative review of real-world data on the safety of nintedanib in patients with idiopathic pulmonary fibrosis. Adv Ther. 2023;40(5):2038\u201350.","journal-title":"Adv Ther"},{"issue":"11","key":"3090_CR41","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1136\/annrheumdis-2020-217331","volume":"79","author":"JR Seibold","year":"2020","unstructured":"Seibold JR, Maher TM, Highland KB, Assassi S, Azuma A, Hummers LK, et al. Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial. Ann Rheum Dis. 2020;79(11):1478\u201384.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3090_CR42","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S2213-2600(20)30330-1","volume":"9","author":"KB Highland","year":"2021","unstructured":"Highland KB, Distler O, Kuwana M, Allanore Y, Assassi S, Azuma A, et al. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. Lancet Respir Med. 2021;9(1):96\u2013106.","journal-title":"Lancet Respir Med"},{"issue":"10","key":"3090_CR43","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/acr2.11483","volume":"4","author":"S Assassi","year":"2022","unstructured":"Assassi S, Distler O, Allanore Y, Ogura T, Varga J, Vettori S, et al. Effect of nintedanib on progression of systemic sclerosis-associated interstitial lung disease over 100 weeks: data from a randomized controlled trial. ACR Open Rheumatol. 2022;4(10):837\u201344.","journal-title":"ACR Open Rheumatol"},{"issue":"12","key":"3090_CR44","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1136\/ard-2022-222564","volume":"81","author":"Y Allanore","year":"2022","unstructured":"Allanore Y, Vonk MC, Distler O, Azuma A, Mayes MD, Gahlemann M, et al. Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON. Ann Rheum Dis. 2022;81(12):1722\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"18","key":"3090_CR45","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718\u201327.","journal-title":"N Engl J Med"},{"issue":"9779","key":"3090_CR46","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","volume":"377","author":"PW Noble","year":"2011","unstructured":"Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760\u20139.","journal-title":"Lancet"},{"issue":"5","key":"3090_CR47","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","volume":"9","author":"J Behr","year":"2021","unstructured":"Behr J, Prasse A, Kreuter M, Johow J, Rabe KF, Bonella F, et al. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021;9(5):476\u201386.","journal-title":"Lancet Respir Med"},{"issue":"9","key":"3090_CR48","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.3899\/jrheum.151322","volume":"43","author":"D Khanna","year":"2016","unstructured":"Khanna D, Albera C, Fischer A, Khalidi N, Raghu G, Chung L, et al. An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial. J Rheumatol. 2016;43(9):1672\u20139.","journal-title":"J Rheumatol"},{"issue":"1","key":"3090_CR49","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S2213-2600(22)00260-0","volume":"11","author":"JJ Solomon","year":"2023","unstructured":"Solomon JJ, Danoff SK, Woodhead FA, Hurwitz S, Maurer R, Glaspole I, et al. Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Respir Med. 2023;11(1):87\u201396.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"3090_CR50","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1703327","volume":"378","author":"KM Sullivan","year":"2018","unstructured":"Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, et al. Myeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med. 2018;378(1):35\u201347.","journal-title":"N Engl J Med"},{"issue":"24","key":"3090_CR51","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1001\/jama.2014.6368","volume":"311","author":"JM van Laar","year":"2014","unstructured":"van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 2014;311(24):2490\u20138.","journal-title":"JAMA"},{"issue":"9790","key":"3090_CR52","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","volume":"378","author":"RK Burt","year":"2011","unstructured":"Burt RK, Shah SJ, Dill K, Grant T, Gheorghiade M, Schroeder J, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet. 2011;378(9790):498\u2013506.","journal-title":"Lancet"},{"issue":"1","key":"3090_CR53","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/bmt.2016.211","volume":"52","author":"N Del Papa","year":"2017","unstructured":"Del Papa N, Onida F, Zaccara E, Saporiti G, Maglione W, Tagliaferri E, et al. Autologous hematopoietic stem cell transplantation has better outcomes than conventional therapies in patients with rapidly progressive systemic sclerosis. Bone Marrow Transplant. 2017;52(1):53\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"3090_CR54","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3324\/haematol.2019.230128","volume":"106","author":"J Henes","year":"2021","unstructured":"Henes J, Oliveira MC, Labopin M, Badoglio M, Scherer HU, Del Papa N, et al. Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party. Haematologica. 2021;106(2):375\u201383.","journal-title":"Haematologica"},{"issue":"5","key":"3090_CR55","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1186\/s13075-014-0435-y","volume":"16","author":"JJ Lee","year":"2014","unstructured":"Lee JJ, Pope JE. A meta-analysis of the risk of venous thromboembolism in inflammatory rheumatic diseases. Arthritis Res Ther. 2014;16(5):435.","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"3090_CR56","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.healun.2018.03.003","volume":"37","author":"P Pradere","year":"2018","unstructured":"Pradere P, Tudorache I, Magnusson J, Savale L, Brugiere O, Douvry B, et al. Lung transplantation for scleroderma lung disease: an international, multicenter, observational cohort study. J Heart Lung Transplant. 2018;37(7):903\u201311.","journal-title":"J Heart Lung Transplant"},{"issue":"11","key":"3090_CR57","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.healun.2021.07.014","volume":"40","author":"MM Crespo","year":"2021","unstructured":"Crespo MM, Lease ED, Sole A, Sandorfi N, Snyder LD, Berry GJ, et al. ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part I: Epidemiology, assessment of extrapulmonary conditions, candidate evaluation, selection criteria, and pathology statements. J Heart Lung Transplant. 2021;40(11):1251\u201366.","journal-title":"J Heart Lung Transplant"}],"updated-by":[{"DOI":"10.1186\/s13075-023-03123-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000}}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-023-03090-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-023-03090-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-023-03090-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T07:05:38Z","timestamp":1690441538000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-023-03090-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,8]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3090"],"URL":"https:\/\/doi.org\/10.1186\/s13075-023-03090-y","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s13075-023-03123-6","asserted-by":"object"}]},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,8]]},"assertion":[{"value":"7 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13075-023-03123-6","URL":"https:\/\/doi.org\/10.1186\/s13075-023-03123-6","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MH is a member of an Advisory Board for Boehringer Ingelheim and has received consulting fees from ImmuneID. MH has received funding from Boehringer Ingelheim and Kadmon Pharmaceutical for investigator-initiated research proposals.JPHS and AM have no disclosures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"118"}}